阿琳娜:另一个迈向LDCT肺癌查在从不吸烟者的未来的石?
Misako Nagasaka1, Catherine T Ly1, Sai-Hong Ignatius Ou1
1University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.
Med (New York, N.Y.)
|July 13, 2024
概括
ALINA试验显示,与化疗相比,辅助性alectinib显著改善了早期ALK阳性非小细胞肺癌患者的存活率. 对从未吸烟者进行肺癌查可能有助于早期识别这些患者.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 药理疗法 药理疗法 药理疗法
背景情况:
- 早期非小细胞肺癌 (NSCLC) 治疗历来依赖于手术后的化疗.
- 形淋巴瘤激酶阳性 (ALK+) NSCLC代表了一组可能受益于向治疗的患者.
- 辅助疗法旨在消除残留的癌细胞,并防止手术切除后的复发.
研究的目的:
- 为了比较辅助性alectinib与白金双重化疗在切除早期ALK+NSCLC的患者中的疗效.
- 评估alectinib对整体生存 (OS) 和中枢神经系统 (CNS) 无病生存 (CNS-DFS) 的影响.
- 评估低剂量计算机断层扫描 (LDCT) 查在识别风险人群 (包括从未吸烟者) 中的潜在作用.
主要方法:
- ALINA试验是一项随机对照研究,将辅助性alectinib与白金双重化疗进行比较.
- 参与者包括患有切除期IB (≥4厘米) 到IIIA ALK+ NSCLC的患者.
- 关键的终点是2年的OS和2年的CNS-DFS.
主要成果:
- 与化疗相比,辅助性alectinib在两年的OS和两年的CNS-DFS中都显示出了统计学上显著的改善.
- 阿莱克提尼布在预防中枢神经系统复发方面表现出卓越的疗效,这是ALK+ NSCLC中已知的模式.
- 在ALINA试验中,很大一部分患者 (60%) 是从未吸烟者,这突显了这一人口统计学特征.
结论:
- 两年的辅助性alectinib是一种优越的治疗策略,比双化学疗法更好,用于切除早期的ALK + NSCLC.
- 阿列克提尼布显著降低了系统性和中枢神经系统复发的风险.
- 在从未吸烟者中使用LDCT进行有针对性的查可能对早期检测ALK+NSCLC至关重要.
更多相关视频
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.6K
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...